TCT-453 Four Years Clinical Outcomes of Overlapping Everolimus-Eluting Stents compared with Sirolimus-Eluting Stents  by Kim, Dong-Bin et al.
B186 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5Number of patients 24Number of lesions treated 57Number of stents placed 61Stent length, diameter (mm) 17.36.27mm, 2.930.56mm
Length of follow-up 20.815.0 months
Retransplantation 1/24MI/Mortality 1/24Angiographic Follow-up 6-12mo 2y 3y 4y
Binary restenosis 4.91% (3/61) 5.13% (2/39) 6.25% (2/32) 11.8% (2/17)Target lesion revascularization 7.02% (4/57) 5.41% (2/37) 6.67% (2/30) 12.5% (2/16)Quantitative coronary angiography (QCA)Pre-procedure Post-procedure* Follow-upy p-valueReference vessel diameter (mm) 2.520.77 2.790.72 2.760.57 *<0.01, y0.02
Minimal lumen diameter (mm) 0.680.37 2.530.66 2.420.66 *<0.01, y<0.01
Diameter stenosis (%) 71.815.0 9.034.14 13.112.9 *<0.01, y<0.01Paired t-test for pre-procedural values compared to post-procedure*, follow-upy
CATEGORIES CORONARY: PCI Outcomes
KEYWORDS Cardiac allograft vasculopathy, Drug-eluting stent, sec-
ond generation, Heart transplant
TCT-453
Four Years Clinical Outcomes of Overlapping Everolimus-Eluting Stents
compared with Sirolimus-Eluting Stents
Dong-Bin Kim,1 Sung-Ho Her,2 Pum Joon Kim,1 Chul Soo Park,3
Jong Min Lee,4 Kiyuk Chang,5 Hee-Yeol Kim,6 Ki Dong Yoo,7
Doo Soo Jeon,8 Wook Sung Chung,9 Ki-Bae Seung5
1The Catholic University of Korea, Seoul, Korea, Republic of; 2Daejeon
St. Mary’s Hospital, Daejeon, Daejeon; 3Yeouido St Mary’s Hospital,
Seoul, Korea, Republic of; 4The Catholic University of Korea, Uijeongbu
St Mary’s Hospital, Gyeonggi-do, Korea, Republic of; 5The Catholic
University of Korea, Seoul St. Mary’s Hospital, Seoul, Korea, Republic
of; 6Division of Cardiology, The Catholic University of Korea, Bucheon,
Korea, Republic of; 7The Catholic University of Korea, St Vincent’s
Hospital, Gyeonggi-do, Korea, Republic of; 8The Catholic University of
Korea, Incheon St Mary’s Hospital, Incheon, Korea, Republic of; 9N/A,
South Korea
BACKGROUND The long-term safety and efﬁcacy of stent overlap
with second-generation drug-eluting stents (DES) have not been well
established. We evaluated long-term clinical outcomes of overlapping
everolimus-eluting stent (EES), as compared with sirolimus-eluting
stent (SES).
METHODS This study was conducted on a multicenter database of
percutaneous coronary intervention with DES. 903 Patients (SES,
n¼537; EES, n¼366) were enrolled based on the following inclusion
criteria: (1) patient receiving two overlapping SES or EES, and (2)
follow-up period of at least four years. We evaluated major adverse
cardiovascular event (MACE), deﬁned as the composite of all-cause
death, non-fatal myocardial infarction (MI) or target lesion revascu-
larization (TLR).
RESULTS During the four years, follow-up EES showed a lower rate of
MACE and TLR rate, as compared to SES (13% vs. 19%, p¼0.027; 3% vs.
7% p¼0.014, respectively). All-cause deaths and non-fatal MI rates
were not signiﬁcantly different between the EES and SES groups (9%
vs. 9%, p¼0.734; 2% vs. 3%, p¼0.259, respectively). After propensity-
score matching, the MACE and TLR of rate of EES group were signif-
icantly lower than those of SES group.
CONCLUSIONS Overlapping EES showed a signiﬁcant lower rate in
MACE and TLR, as compared to SES, in the long-term clinical follow-
up.
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BACKGROUND Aspirin forms a crucial backbone of the Antiplatelet
pharmacotherapy in patients undergoing percutaneous coronaryintervention (PCI). However, there is uncertainty regarding the
optimal dose to be prescribed. We aim to perform a systematic liter-
ature review on all studies comparing treatment with low and high
dose aspirin in patients undergoing PCI.
METHODS A comprehensive literature search was performed by 2
independent reviewers utilizing MEDLINE, EMBASE and Cochrane
Library databases. All trials comparing low dose and high dose aspirin
in patients undergoing PCI were selected. Low dose was deﬁned
as <162mg and high dose as 162mg. Outcomes measured included
major adverse cardiovascular events (MACE), deﬁned as the
composite of death, reinfarction, stroke and target vessel revascular-
ization, and bleeding. In combining evidence across the trials, a ﬁxed-
effect method in RevMan 5.3 was used after ruling out heterogeneity
based on the I2 test (I2<40%) to obtain hazards ratios for the
outcomes.
RESULTS Five studies with a total of 27,456 patients were selected.
Two studies evaluated outcomes at 30 days and three studies at 1
year. No signiﬁcant difference was found in MACE rates when eval-
uating low dose against high dose aspirin (HR [95% CI], 1.03 [0.93-
1.15]; p¼0.55). Bleeding rates were signiﬁcantly lower in the low dose
aspirin group as compared to the high dose group (HR [95% CI], 0.64
[0.50-0.83]; p¼0.0005). Two studies reporting stent thrombosis rates
did not show any difference between both groups.
CONCLUSIONS Although there was no signiﬁcant difference in MACE
rates between the high and low dose aspirin groups, the high dose
aspirin group appeared to be at a signiﬁcantly increased risk of
bleeding complications. This lends weight to the use of low dose
aspirin in patients undergoing PCI.
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BACKGROUND Whether a smoker’s paradox exists with regards to
early and late mortality outcomes for patients undergoing percuta-
neous coronary intervention (PCI) for acute coronary syndrome (ACS)
is debated. Studies have produced inconclusive data on whether such
a paradox exists or whether it can be explained by confounding
